TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06194734
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel intravenously administered at 60-75 mg/m2 once every 3 weeks；
Study: NCT06194734
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 orally administered 40-60mg Bid on Day 1 to Day 14 of every 3 weeks, 21 days as a cycle
Study: NCT05489406
Drug: DTG DT (6 x 5 mg)
Normalized name: L-DT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DTG 5mg dispersible tablet
Study: NCT00034463
Drug: ALIMTA
Normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00034463
Drug: multi-vitamins
Normalized name: Multi-vitamins Tablet
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06176716
Drug: ET-26
Normalized name: Chloride/Dextrose/Potassium/Sodium 290 MG/1 PACKET-6 GM/1 PACKET-180 MG/1 PACKET-260 MG/1 PACKET Oral Powder for Solution
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Study: NCT05608343
Drug: Difamilast
Normalized name: Difamilast
DrugBank: Difamilast (DB14987)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Off-white ointment containing active ingredient, petrolatum and other ingredients
Study: NCT06117371
Drug: BEBT-607Tablets
Normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhaseⅠa:100mg,200mg,300mg,400mg,600mg or 800mg/day,50mg,100mg,150mg,200mg,300mg or 400mg each time, once a day in the single administration phase and twice a day in the continuous administration phase (only once on the 28th day of the first cycle) for 28 days,28 days is as a treatment cycle.~PhaseⅠb:300mg,400mg or 600mg/day, 150mg,200mg or 300mg each time,twice a day (only once on day 1 and day 28 of the first cycle), continuous administration for 28 days,28 days is as a treatment cycle.
Study: NCT06158334
Drug: Describe the respective haemostatic efficacy of Elocta® for haemopilia A during surgical procedures
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All surgical data will be collected: surgery, biology, administration of Elocta®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding
Study: NCT06158334
Drug: Describe the respective haemostatic efficacy of Alprolix® for haemopilia B during surgical procedures
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All surgical data will be collected: surgery, biology, administration of Alprolix®, bleeding and transfusion, hemostatic efficacity, surgery complication and bleeding...
Study: NCT04701333
Drug: Cabergoline 1 MG
Normalized name: cabergoline 1 MG
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine agonist
Study: NCT05011227
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles Camrelizumab before endoscopic surgery and one year after
Study: NCT00962481
Drug: Bimosiamose
Normalized name: Bimosiamose
DrugBank: Bimosiamose (DB06197)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05622656
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 0.0005%
Study: NCT05076435
Drug: Isotonic crystalloids
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Types of fluids in both intervention groups:~* Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency~* Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used.~* Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy.
Study: NCT00002164
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04984070
Drug: Metformin Pill
Normalized name: metformin Pill
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin is used to lower insulin resistance or to modulate hyperinsulinism.
Study: NCT05500664
Drug: Lavender Oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: three drops of the designated lavender will be placed on a 2-inch by 2-inch impermeable, backed gauze pad and patient was asked to inhale deeply for 5 minutes
Study: NCT05375188
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DOSAGE FORM: IV Infusion DOSAGE: 0.4 mcg/kg/hr
Study: NCT05137496
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3mg/kg/d, iv.gtt, for at least 2 weeks
Study: NCT05137496
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
Study: NCT04830930
Drug: CKD-381
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose, oral administration of CKD-381 1 tablet
Study: NCT06020898
Drug: Sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with acute ischemic stroke included in the study are randomly assigned to low-dose sodium valproate group, high-dose sodium valproate group and placebo group. Besides receiving conventional treatment for stroke, 10mg/kg sodium valproate, 20mg/kg sodium valproate or normal saline were given intravenously for 3 consecutive days, respectively.
Study: NCT05055544
Drug: Fosfomycin
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of fosfomycin (3 g) powder dissolved in 75 ml water and 2 placebo tablets t.i.d. for 7 days (group A),
Study: NCT05625334
Drug: ASA
Normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: powder for oral inhalation via a Dry Powder Inhaler (DPI)
Study: NCT05174065
Drug: Apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablets
Study: NCT04502537
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral
Study: NCT04502537
Drug: erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection
Study: NCT03990896
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells.
Study: NCT05640791
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2；d1, 8, 21 d cycle
Study: NCT05640791
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2；d1, 8, 21 d cycle
Study: NCT05640791
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/m2；d1, 8, 21 d cycle
Study: NCT05640791
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000mg；d1, 21 d cycle
Study: NCT04835870
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib-160mg bid PO d0-d20(1-21d)
Study: NCT04835870
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-375 mg/m2 i.v d0 (/21d)
Study: NCT04835870
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine-1.4 mg/m2 i.v d1 (/21d)(2 mg max)
Study: NCT04835870
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone-100 mg p.o d1-d5 (/21d)
Study: NCT05839574
Drug: MTX + letrozole add-on
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTX in a single dose of 100 mg intravenously and 50 mg in intra-amniotic injection (day 0), along with 30 mg potassium chloride in case of positive fetal heartbeat (FH) + Letrozole in a daily dose of 5 mg (2 x 2.5 mg) orally for 10 days from day 0, and subsequent hysteroscopic evacuation of products of conception (POC)
Study: NCT05567822
Drug: Esmolol Hydrochloride
Normalized name: Esmolol Hydrochloride
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the esmolol group, patients will receive a bolus dose of esmolol followed by a continuous infusion of esmolol intraoperatively
Study: NCT05500807
Drug: Emicizumab
Normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection of emicizumab for prophylaxis
Study: NCT00000699
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000699
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05206149
Drug: Intranasal glugagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
Study: NCT06124963
Drug: WX390
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: WX390 tablet, 0.9 mg once a day
Study: NCT06124963
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg, Day 1, every 3 weeks
Study: NCT05184946
Drug: Camrelizumab Combined with SOX
Normalized name: miconazole
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
Study: NCT05062005
Drug: Concurrent Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m², Q3w.
Study: NCT05073562
Drug: Mebendazole Pill
Normalized name: mebendazole Pill
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One-time deworming treatment with mebendazole.
Study: NCT05982990
Drug: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 inhalations in one study period
Study: NCT05751746
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate will be administered following a protocol that obstetricians already use in our hospital.
Study: NCT04767698
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg SC weekly for 36 months
Study: NCT04767698
Drug: Short-course Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
Study: NCT04767698
Drug: Continued Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
Study: NCT04951362
Drug: intranasal spray ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal spray of saline
Study: NCT06075212
Drug: blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
Study: NCT05579977
Drug: PF-07081532
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucagon-like peptide-1 receptor agonist
Study: NCT05579977
Drug: Rybelsus
Normalized name: Rybelsus
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Semaglutide
Study: NCT05392608
Drug: Alpelisib 150 MG Oral Tablet [Piqray]
Normalized name: alpelisib 150 MG Oral Tablet [Piqray]
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib 300mg once daily (may be reduced to 1dd250 or 1dd200mg in case of toxicity)
Study: NCT05392608
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 300mg 1x/four weeks
Study: NCT05299398
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone capsule once daily
Study: NCT04955171
Drug: BEOVU intravitreal injection
Normalized name: Beovu
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BEOVU intravitreal injection
Study: NCT00006591
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00006591
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05543837
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a fixed dose of capsaicin
Study: NCT06383832
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin tablets oral 10mg/d qd, intervention for 12 weeks.
Study: NCT01567683
Drug: Imiquimod (topical use)
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05538585
Drug: Galicaftor
Normalized name: Galicaftor
DrugBank: Galicaftor (DB14894)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT05538585
Drug: Navocaftor
Normalized name: Navocaftor
DrugBank: Navocaftor (DB19039)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06255795
Drug: chidamide, anti-PD1 antibody, and pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
Study: NCT06255795
Drug: DDGP
Normalized name: Dapagliflozin and Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
Study: NCT03796507
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
Study: NCT05003037
Drug: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5\~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
Study: NCT04763044
Drug: 0 ppm F
Normalized name: Sodium Fluoride 6 mg in 1 mL DENTAL PASTE, DENTIFRICE [Sodium Fluoride 5000 ppm Fruit]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study: NCT04968158
Drug: Etoricoxib 90 mg / Tramadol 50 mg
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
Study: NCT05975749
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab: 4.5mg/Kg on day 1
Study: NCT05975749
Drug: Trastuzuma
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
Study: NCT05481463
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: surufatinib,250mg, qd, po, 28 days for a cycle
Study: NCT05481463
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
Study: NCT03643198
Drug: ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)
Normalized name: metronidazole and diloxanide
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
Study: NCT05599256
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens.
Study: NCT05650268
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
Study: NCT06247085
Drug: Pegtibatinase
Normalized name: Pegtibatinase
DrugBank: Pegtibatinase (DB17677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full Target Dose of pegtibatinase BIW
Study: NCT04703088
Drug: Ondansetron 4 MG
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
Study: NCT06012682
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin
Study: NCT05255523
Drug: pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
Study: NCT04891458
Drug: Patients received lighter sedation with propofol after spinal anesthesia.
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MOAA/S 0-2.
Study: NCT04891458
Drug: Patients received heavier sedation with propofol after spinal anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MOAA/S 3-5.
Study: NCT04891458
Drug: Patients received lighter sedation with dexmedetomidine after spinal anesthesia
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MOAA/S 0-2.
Study: NCT04891458
Drug: Patients received heavier sedation with dexmedetomidine after spinal anesthesia.
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MOAA/S 3-5.
Study: NCT05057481
Drug: Mycophenolate Mofetil 500mg
Normalized name: MYCOPHENOLATE MOFETIL 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF 2gram/day orally for 12 weeks
Study: NCT05057481
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
Study: NCT01132794
Drug: Intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
Study: NCT05772624
Drug: low dose nivolumab in combination with AVD
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab as an standard dose of 40mg in combination with AVD.
Study: NCT03624842
Drug: Trappsol (R) Cyclo (TM)
Normalized name: pantolactone, (R)-
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no